SCHEMBL5160710

SCHEMBL5160710

CCCCC(CC)COC(=O)CC(=O)c1ccoc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.51
TSHR P16473 5/20 0.51
TDP1 Q9NUW8 2/20 0.51
ATM Q13315 1/20 0.51
ALDH1A1 P00352 5/20 0.49
CA2 P00918 1/20 0.49
LMNA P02545 3/20 0.47
MAPK1 P28482 3/20 0.47
HSD17B10 Q99714 1/20 0.47
RECQL P46063 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
TRPA1 O75762 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP14 P50281 1/20 0.35
PTK2 Q05397 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1201268 0.82 ALDH1A1 (0.60) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL1200573 0.81 CYP3A4 (0.55) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL5160563 0.80 CYP3A4 (0.54) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL5158654 0.78 CYP3A4 (0.51) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL5158161 0.78 TSHR (0.51) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL7097300 0.78 ALDH1A1 (0.52) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL5158368 0.78 CYP3A4 (0.54) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL5162390 0.77 CYP3A4 (0.50) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL1642808 0.77 KMT2A (0.49) CYP3A4TSHRALDH1A1MAPK1HSD17B10
SCHEMBL2215691 0.77 CYP3A4 (0.77) CYP3A4TSHRTDP1ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CYP3A4 7/4885TSHR 4474/4885TDP1 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.